©The Author(s) 2024.
World J Gastrointest Oncol. Mar 15, 2024; 16(3): 933-944
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.933
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.933
Table 3 Pathologic results of 45 patients with rectal cancer who underwent transanal endoscopic intersphincteric resection
| Characteristic | Data |
| Pathological T stage | |
| T1 | 3 (6.67) |
| T2 | 32 (71.11) |
| T3 | 10 (22.22) |
| Pathological N stage | |
| N0 | 31 (68.89) |
| N1 | 10 (22.22) |
| N2 | 4 (8.89) |
| Pathological TNM stage | |
| I | 24 (53.33) |
| II | 7 (15.56) |
| III | 14 (31.11) |
| Tumor size in cm | 2.86 (0.80-4.60) |
| Number of lymph nodes harvested | 19.56 (8-40) |
| Number of positive lymph nodes | 0.91 (0-7.0) |
| Length between tumor and DRM in cm | 2.30 ± 0.62 |
| CRM status | |
| Positive | 0 |
| Negative | 45 (100) |
| DRM status | |
| Positive | 0 |
| Negative | 45 (100) |
- Citation: Xu ZW, Zhu JT, Bai HY, Yu XJ, Hong QQ, You J. Clinical efficacy and pathological outcomes of transanal endoscopic intersphincteric resection for low rectal cancer. World J Gastrointest Oncol 2024; 16(3): 933-944
- URL: https://www.wjgnet.com/1948-5204/full/v16/i3/933.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i3.933